New Parkinson's drug candidate takes first step in human safety trial
Knowledge-focused
Completed
This early-stage study tested a new oral drug, ATH-399A, in 76 healthy adults to see if it is safe and how the body processes it. The goal is to gather information needed to develop a treatment for Parkinson's disease. Participants took single or multiple doses, and researchers m…
Phase: PHASE1 • Sponsor: HanAll BioPharma Co., Ltd. • Aim: Knowledge-focused
Last updated May 01, 2026 16:00 UTC